Autolus Therapeutics (NASDAQ:AUTL) Reaches New 12-Month Low – What’s Next?

Autolus Therapeutics plc (NASDAQ:AUTL) hit a new 52-week low on Tuesday . The stock traded as low as $2.07 and last traded at $2.14, with a volume of 322885 shares trading hands. The stock had previously closed at $2.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on AUTL shares. The Goldman Sachs Group raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and increased their price target for the stock from $7.00 to $7.60 in a report on Monday, November 18th. Redburn Atlantic upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 price objective for the company in a report on Friday, November 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Monday, January 13th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $10.40.

Autolus Therapeutics Trading Up 3.1 %

The stock has a 50 day moving average price of $2.51 and a 200 day moving average price of $3.42. The company has a market cap of $578.75 million, a PE ratio of -1.80 and a beta of 2.02.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the company posted ($0.26) earnings per share. Equities analysts expect that Autolus Therapeutics plc will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Dumont & Blake Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter worth $35,000. ProShare Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the 2nd quarter valued at about $43,000. Arkadios Wealth Advisors bought a new position in shares of Autolus Therapeutics in the 4th quarter worth approximately $47,000. Capstone Investment Advisors LLC purchased a new position in shares of Autolus Therapeutics in the third quarter worth approximately $51,000. Finally, Avanza Fonder AB bought a new stake in Autolus Therapeutics during the fourth quarter valued at approximately $75,000. Hedge funds and other institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.